Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Disturbances of blood coagulation often occur in various malignancies. Deep vein thrombosis or pulmonary embolism often precedes the manifestation of a solid tumour. Chemotherapy, irradiation, surgery, infections are the triggering factors of a blood clotting abnormality. In the present paper the plasmatic clotting factors and platelet functions were studied in patient with solid tumour and with lymphoma. The most characteristic findings were: ethanol positivity, increased fibrinogen level, decreased euglobulin lysis, impairment of platelet functions. In solid tumours the signs of hypercoagulability were more expressed, in non-Hodgkin lymphomas the platelet functions were decreased. These data were in good correlation with data in the literature: in tumours and lymphomas an activation of blood clotting and platelets can be observed.
 ...
PMID:Haemostatic alterations in lymphomas and tumours. 367 Oct 21

Haemostasis was studied in 26 patients with malignant non-Hodgkin lymphoma and 19 patients with solid tumours before, and for four days after combined chemotherapy. After treatment an activation of haemostasis was observed in both groups, especially on the 1st and 2nd days. Activation was more expressed in the lymphoma group. This manifested with an increased fibrinogen level, positivity of the ethanol test, a prolongation of thrombin time, an increase of euglobulin lysis and of some platelet functions. Prothrombin and AT III activity decreased as signs of consumption. Thromboembolic events were in the lymphoma group in connection with combined chemotherapy. Thus for preventing the activation of haemostasis we suggest a low-dose subcutaneous heparin treatment for 4 days, beginning 2 h before cytostatic therapy.
 ...
PMID:Activation of haemostasis by combined chemotherapy. 367 Oct 22

The usefulness of radioiodinated fibrinogen in tumor localization and of coagulation in 80 cancer patients was investigated. Tumors externally detected demonstrated positive localization in 63% of all cases and in 100% of osteosarcomas of limbs. Fibrinogen half-life was reduced in cancer patients particularly in cases with lymphoma, Hodgkin's disease and osteosarcoma irrespectively of basal plasma fibrinogen levels. In lymphoma and ovarian cancer, fibrinogen degradation products were correlated to radiofibrinogen T/2 reduction. In patients with the lowest fibrinogen T/2 and platelet count, heparin infusion therapy returned the fibrinogen half-life to normal range. Present results suggest the existence of enhanced coagulation both inside and around the tumor and/or dissemination in early cancer as well as in the more advanced stage.
 ...
PMID:Radioiodinated fibrinogen distribution in cancer patients. 615 67

Forty-four patients (9 stage II, 15 sage III, 7 stage IV, and 13 in complete remission) with Hodgkin's disease without any clinical coagulation disorder were studied. Fibrinogen behavior was evaluated by measuring fibrinogen level and using 1251-fibrinogen, the half-life, survival and fibrinogen turnover. Platelet count and fibrinogen/fibrin degradation products (FDP) were also assayed. The fibrinogen half-life, survival and turnover were significantly longer and faster, than those found in 10 healthy subjects, in stage II, III and IV subjects (p less than 0.001, p less than 0.001, p less than 0.05 for stage II; p less than 0.001, p less than 0.001, p less than 0.001 for stage III; p less than 0.005, p less than 0.005, p less than 0.001 for stage IV, respectively). In most cases, FDP values were within the normal range, although they were significantly higher than those of control group in stages III and IV. Intravascular coagulation and fibrinolysis were not found in the 13 patients with complete remission. In these patients, the behavior of fibrinogen was normal, suggesting that the parameters studied are related to the presence of the tumor, and can be useful in monitoring the state of remission.
 ...
PMID:The evaluation of fibrinogen behavior in Hodgkin's disease: correlation with clinical stage. 667 30

Reed-Sternberg cells in the lymph nodes from five patients with Hodgkin's disease were studied. Indirect immunofluorescence on fixed sections with a monospecific anti-serum to fibronectin revealed abundant cytoplasmic fibronectin in approximately 90% of the Reed-Sternberg cells. In addition, the cells were shown by immunofluorescence to contain polyclonal IgG; however, factor VIII antigen, albumin, fibrinogen, alpha-2-macroglobulin, anti-thrombin III, and ceruloplasmin were not present. The abundant cytoplasmic fibronectin suggests that Reed-Sternberg cells are derived from tissue macrophages.
 ...
PMID:Reed-Sternberg cells in Hodgkin's disease contain fibronectin. 700 37

In an immunohistochemical study of 26 biopsies from 24 patients with Hodgkin's disease a granular staining pattern for alpha-1-antitrypsin (alpha(1)AT) and alpha-1-antichymotrypsin (alpha(1)ACT) was seen in Reed-Sternberg (RS) cells and mononuclear Hodgkin's (H) cells in over half the cases. The pattern of staining for these antiproteases seen in RS and H cells has previously only been observed in normal and malignant cells of the monocyte/macrophage lineage within the lymphoreticular system. A faintly granular evenly distributed staining for IgG was found in viable RS and H cells. This staining was associated with a similar distribution of both light chains but not J chain, suggesting that the immunoglobulin had not been synthesised by these cells but had been taken up from the extracellular environment. It is suggested that this uptake is an active process occurring in viable RS and H cells, possibly via Fcgamma receptors and further supports an origin from cells of the monocyte/macrophage lineage. IgA, IgD, albumin, fibrinogen, C1q, C4 and C3 were present in some cells, IgM was more rarely found and lysozyme was absent. The fact that cells staining for these serum proteins generally showed signs of degeneration and that the extent of staining correlated with the molecular weight, but not serum concentration, of the protein suggests that they are passively acquired by dead or dying cells and thus represent a separate phenomenon from IgG uptake. The function of IgG uptake and accumulation by RS cells and the alpha(1)AT and alpha(1)ACT markers may prove of use in identifying the macrophage subtype from which these cells are derived.
 ...
PMID:Macrophage origin of Reed-Sternberg cells: an immunohistochemical study. 704 Apr 82

Fibrinogen levels were investigated in the plasma of a group of patients with malignant lymphoma consisting of M. Hodgkin's and non-Hodgkin's lymphoma, and were found to be significantly higher in an acute onset of the disease and in relapses, than in a control group of healthy blood donors. In the terminal stages, fibrinogen levels in the plasma were observed to decline towards the upper normal limits. Plasma fibrinogen levels are considered to be a good indicator of the activity of the disease.
 ...
PMID:Alterations of plasma levels in malignant lymphoma. 729 Feb 61

No significant excess of deep vein thrombosis (DVT) as measured by the 125I-labelled fibrinogen method was observed in patients having staging laparotomy and splenectomy for Hodgkin's disease (HD) compared with patients having elective cholecystectomy under highly standardized surgical conditions. Patients who did have DVT all had splenic involvement with HD. There was no correlation between the post-splenectomy thrombocytosis and the occurrence of DVT. Patients with non-Hodgkin's lymphoma (NHL) and splenomegaly had a high incidence of DVT after splenectomy.
 ...
PMID:Thrombotic risks of staging laparotomy with splenectomy in Hodgkin's disease. 731 64

Hemostatic abnormalities are rather frequent in cancer patients either in hematological or in solid tumors. Acute disseminated intravascular coagulation (DIC) is a rare coagulopathy in cancer patients, but when it develops it becomes rapidly fatal. Between June 1988 and December 1992 we observed 8 cases of acute DIC occurring in gastric cancer (4 patients), breast cancer (3 patients) and high-grade non-Hodgkin lymphoma (1 patient). In 3 patients affected by gastric carcinoma, acute DIC was the first manifestation of the presence of the tumor, while in the other patients DIC occurred during the course of the disease. All the patients were treated with heparin, fresh frozen plasma and platelet support, but only in 1 patient was a short duration improvement of clinical conditions and coagulation tests recorded. Acute DIC can be the first manifestation of gastric tumors and the presence of the hemorrhagic syndrome associated with thrombocytopenia, hypofibrinogenemia and fibrin/fibrinogen degradation products should initiate a search for gastric carcinoma.
 ...
PMID:Acute disseminated intravascular coagulation syndrome in cancer patients. 747 40

A prospective study was performed to assess the use of plasma measurement of tumour necrosis factor (TNF), lymphotoxin alpha (LT alpha) and their soluble receptors (p55 and p75) for prognostic risk assignment in 61 patients with Hodgkin's disease. Plasma levels of TNF, p55 and p75, but not of LT alpha, were higher in Hodgkin's disease patients than in healthy controls. Plasma levels of TNF, p55 and p75 were associated with several prognostic factors for Hodgkin's disease, including those related to the host (age, performance status) and to the tumour (disease stage, extranodal site involvement, bulky tumour, serum levels of LDH and beta2-microglobulin, histology). Elevated plasma levels of TNF, p55 and p75 were also associated with several parameters reflecting an immune activation, including the presence of B symptoms, elevated serum levels of gammaglobulins, alkaline phosphatase and fibrinogen, as well as peripheral monocytosis, anaemia and low serum albumin levels. Finally, elevated TNF ligand receptor plasma markers were associated with a lower incidence of complete response to therapy and predicted shorter free-from-progression survival and overall survival of the patients. These results indicate that the plasma levels of TNF and its soluble receptors correlate with clinical features and outcome of patients with Hodgkin's disease.
 ...
PMID:Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. 964 58


<< Previous 1 2 3 Next >>